Utah is currently home to 1224 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Salt Lake City, Murray, Ogden and West Jordan. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
NCT04262466
Recruiting
Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2024
Locations: University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Select Advanced Solid Tumors
Register for Updates
ALTO-100 in Bipolar Disorder with Depression (BD-D)
NCT06656416
Recruiting
The purpose of this study is to assess antidepressant efficacy differences between ALTO-100 and placebo during the Double-Blind period in patients with bipolar disorder I or II with current major depressive episode, when used adjunctively to a mood stabilizer, related to patient characteristics. Additionally, safety, tolerability, and efficacy will be assessed in a subsequent open label treatment period.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
10/22/2024
Locations: Site 6121, Draper, Utah
Conditions: Bipolar Disorder I or II with a Major Depressive Episode
Register for Updates
G7 Acetabular System with Vivacit-E or Longevity Liner PMCF Study
NCT04754087
Recruiting
The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Acetabular Shells when used with the Vivacit-E and Longevity HXLPE liners and instrumentation in primary and revision total hip arthroplasty.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/22/2024
Locations: University of Utah Health, Salt Lake City, Utah
Conditions: Total Hip Arthroplasty, Degenerative Joint Disease of Hip, Avascular Necrosis of Hip, Rheumatoid Arthritis of Hip, Osteoarthritis, Hip, Osteoarthritis of Hip, Fractures, Hip, Fracture of Hip
Register for Updates
REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients
NCT04687358
Recruiting
The registry will focus on furthering the understanding of the natural history of recurrent pericarditis (RP), as well as document RP-related clinical, health-related quality of life (HRQoL), and economic burden and will assist the medical community to refine or develop data-driven recommendations for clinical management of RP patients to optimize clinical outcomes. It also aims to generate data in support of the impact of rilonacept on clinical outcomes in a real-world population.
Gender:
ALL
Ages:
7 years and above
Trial Updated:
10/18/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: Recurrent Pericarditis
Register for Updates
Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
NCT05743244
Recruiting
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.
Gender:
ALL
Ages:
Between 12 years and 35 years
Trial Updated:
10/17/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: Diabetes Mellitus, Type 1
Register for Updates
MiSight 1 Day Post-Approval Study for Effectiveness and Visual Symptoms
NCT05285553
Recruiting
The purpose of this post-approval study is to confirm the effectiveness of the MiSight 1 Day lens in clinical practices within the US and to assess the stability of the myopia reduction over one-year post-treatment.
Gender:
ALL
Ages:
Between 8 years and 12 years
Trial Updated:
10/17/2024
Locations: Utah Eye Centers, Ogden, Utah
Conditions: Myopia
Register for Updates
MiSight 1 Day Safety Post-Approval Study
NCT05285527
Recruiting
The purpose of this post-approval study is to confirm the safety of daily disposable soft contact lens wear among the intended patient population for the MiSight 1 Day lens in the US.
Gender:
ALL
Ages:
Between 8 years and 12 years
Trial Updated:
10/17/2024
Locations: Child & Family Eye Care Center, Pleasant Grove, Utah
Conditions: Myopia
Register for Updates
A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice
NCT04475926
Recruiting
This study will follow participants who are screened and confirmed with a genetic diagnosis of Limb-girdle muscular dystrophy type 2E (LGMD2E/R4), Limb-girdle muscular dystrophy type 2D (LGMD2D/R3), Limb-girdle muscular dystrophy type 2C (LGMD2C/R5), or Limb-girdle muscular dystrophy type 2A (LGMD2A/R1). These enrolled participants will be followed to evaluate mobility and pulmonary function for up to 5 years after enrollment for participants with LGMD2C/R5, LGMD2D/R3, and LGMD2E/R4 with a Nort... Read More
Gender:
ALL
Ages:
4 years and above
Trial Updated:
10/16/2024
Locations: University of Utah Hospital, Salt Lake City, Utah
Conditions: Limb-girdle Muscular Dystrophy
Register for Updates
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
NCT02977780
Recruiting
This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib * Temozolomide (temodar) * Neratinib * CC115 * QBS10072S
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/15/2024
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Glioblastoma
Register for Updates
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636
Recruiting
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (VEGF) therapies ha... Read More
Gender:
ALL
Ages:
Between 50 years and 89 years
Trial Updated:
10/14/2024
Locations: Retina Associates of Utah, Salt Lake City, Utah
Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
Register for Updates
Perform Humeral System Study
NCT05067543
Recruiting
This study is an international, single arm, multicenter, prospective, non-significant risk, Post-Market Clinical Follow-up study, which is designed to collect safety and performance data at baseline, surgery, immediate post-op and annually through 10 years post-operation. Data collected from this study will be used for purposes, including but not limited to, Post-Market Surveillance, peer-reviewed publications, education materials, regulatory submissions, and/or product development.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/14/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: Osteoarthritis Shoulder, Avascular Necrosis, Post-traumatic Arthrosis of Other Joints, Shoulder Region, Rotator Cuff Tear Arthropathy
Register for Updates
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
NCT05021835
Recruiting
This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). This is known as the study medicine. Which treatment participants get is decided by chance. Participants chance of getting ziltivekimab or placebo is the same. Z... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/12/2024
Locations: University of Utah School of Medicine, Salt Lake City, Utah
Conditions: Cardiovascular Risk, Chronic Kidney Disease, Inflammation
Register for Updates